Since the outbreak of SARS-CoV-2, the virus causing COVID-19, interest in air disinfection has increased rapidly. With researchers around the world looking into how the virus has spread so quickly, many arrows are pointing to airborne transmission.
Scientists are investigating how far infectious particles can travel and how long they can stay in the air. There are many forms of PPE (personal protective equipment) that can offer protection for medical professionals in combination with Infection Prevention protocols, but how can you really protect yourself from the invisible enemy?
Viruses can rapidly spread from surfaces, hands and the air. Considering the procedures, we have in place to disinfect hands and surfaces, have you ever considered the procedures we have in place to disinfect the air? Infectious droplet nuclei can remain airborne indefinitely, infecting patients and staff over large distances, with the effects not known until potentially several days later. Infectious droplets can even be suspended in the air for an unknown period of time, increasing the risk of transmission.
In a recent study, the Novaerus Defend 1050, a portable air disinfection device was independently tested and shown to be effective at reducing MS2 Bacteriophage, a surrogate for SARS-CoV-2 (COVID-19), by 99.99% in 15 minutes. A number of hospitals worldwide, including in Wuhan, China, have installed the device to help reduce transmission of SARS-CoV-2. This extra layer of protection, simply working in the background, can help to put the minds of the staff and patients at ease, whilst working in synergy with their infection prevention protocols.
The Novaerus Defend 1050 is helping to close the loop in infection control with 24/7 air disinfection. Designed for rapid remediation in large spaces and situations with high risk of infection, the portable device can easily move to the point of care in one powerful and safe solution. The device can kill airborne pathogens and trap particulate as small as 0.12µm.
The Defend 1050 combines Novaerus patented ultra-low energy plasma technology with a triple-stage filtration system from Camfil®. The technology is powerful yet gentle. With no harmful by-products, it is safe for use around vulnerable patients and staff. This device has been proven safe and effective in dozens of independent laboratory studies.
As countries around the world begin to recover from the current pandemic, medical facilities will need to find ways to adapt and reinforce their standard infection prevention protocols to reduce the risk or impact of a second wave of COVID-19 outbreaks. Combined with the continuous threat of other infectious airborne viruses, bacteria and fungi, this make the unique technology that Novaerus offers unrivalled in the marketplace. This is your chance to close the infection control loop.
The Novaerus product range is distributed by H&R Healthcare in the UK. For any product enquiries please contact customerservices@hrhealthcare.co.uk
